Articles Published in 2011

Clarient, HistroRxR to provide AQUA technology for clinical trials

Tuesday, October 25, 2011 02:38 PM

Clarient, a GE Healthcare company, and HistoRxR have signed a definitive agreement to provide pharma services using AQUA technology to their growing lists of pharma clients.  By implementing HistoRx's AQUA technology in Clarient's CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies' growing need for biomarker analysis in clinical trials.  Use of tissue biomarkers to characterize a patient's tumor is becoming a crucial element of personalized cancer care.

More... »

CoreLab launches semi-automated ECG solution

Tuesday, October 25, 2011 02:07 PM

CoreLab Partners has launched a new semi automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions.

More... »

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

CertiVox wins 2011 Bully Award

Tuesday, October 25, 2011 01:43 PM

CertiVox has received the Yearling category of the 2011 Bully Award, an honor presented by White Bull Summits to Europe’s leading technology, media and telecommunications companies.

More... »

Medical Research Network expands with US office

Tuesday, October 25, 2011 01:21 PM

Medical Research Network (MRN) has opened a US office in Raleigh, North Carolina to better service clients in North America while at its UK headquarters in Milton Keynes, the company has completed a management restructure to allow the leadership team more time to focus on its continued expansion.

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »

Garland joins Exelixis

Tuesday, October 25, 2011 12:52 PM

Exelixis has named J. Scott Garland as executive vice president and chief commercial officer. As the company's chief commercial officer, Gardland will oversee the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

More... »

ProBioGen, Inhibrx ink license agreement

Tuesday, October 25, 2011 12:02 PM

ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms.

More... »

Gilead, GlobeImmune collaborate

Tuesday, October 25, 2011 11:46 AM

Gilead Sciences and GlobeImmune have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.

More... »

S*BIO to initiate phase III myelofibrosis trial

Tuesday, October 25, 2011 11:32 AM

S*BIO plans to initiate a global phase III clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

More... »